U.S. Healthcare Marketing Rules: 3 Actions to Avoid HIPAA, TCPA Risk

Four federal authorities govern healthcare marketing today: HHS/OCR enforces HIPAA’s authorization requirement for PHI used in marketing, the FTC polices deceptive health claims and testimonials, the FCC’s TCPA rules dictate consent for calls and texts, and CMS locks down what you can say to Medicare beneficiaries. Compliance teams should act on three things now: audit every tracking pixel and BAA, rebuild consent capture to meet one-to-one standards, and document every policy decision in writing.

TL;DR:

• Implement signed, detailed HIPAA authorizations for any marketing use of protected health information, ensuring all seven required elements are present.
• Regularly audit tracking pixels, analytics scripts, and third-party vendors to prevent inadvertent protected health information disclosures without proper business associate agreements.
• Capture explicit, topic-specific consent for outbound calls and texts, and ensure revocations are synchronized across all systems within the same day.
• Document all policy decisions, consent captures, and vendor BAAs meticulously to create a reliable audit trail for regulators and auditors.
• Comply with state-specific health privacy laws and Medicare marketing restrictions, maintaining separate workflows and disclosures for different audiences and channels.

Table of Contents

• Healthcare Marketing Rules Under HIPAA: What Counts and What Needs Authorization
• When Communications Aren’t Marketing: HIPAA’s Exceptions
• Tracking Pixels, Analytics, and BAAs: Where Web Tech Creates PHI Risk
• TCPA and the One-to-One Consent Rule: What Changed for Outbound Marketing
• FTC Rules on Health Claims, Reviews, and Testimonials
• CMS Medicare Marketing Rules (MCMG): What’s Different for Medicare Audiences
• A Practical Compliance Checklist for Healthcare Marketing Teams
• Operational Proof Points: Reducing Regulatory Risk With the Right Infrastructure
• State-Specific Healthcare Marketing Regulations That Add to Federal Rules
• Direct-to-Consumer Pharmaceutical Advertising Restrictions
• Social Media and Influencer Marketing Rules in Healthcare
• Patient Testimonials and Endorsements: What Healthcare Marketing Law Restricts
• Patient Data Privacy Beyond HIPAA: GDPR and Other Considerations
• Why Privacy-First Marketing Wins in Healthcare
• Where to Learn More About RevRing’s Healthcare Marketing Tools
• Sources
• FAQ

Healthcare Marketing Rules Under HIPAA: What Counts and What Needs Authorization

HIPAA defines marketing narrowly, but the definition trips up more campaigns than most teams expect. Under 45 CFR 164.501, marketing means any communication about a product or service that encourages someone to purchase or use it, when that communication uses protected health information. A newsletter reminding patients about flu shots crosses into marketing territory the moment it references someone’s specific diagnosis or visit history to target them.

The general rule is blunt: covered entities need signed, written authorization before using or disclosing PHI for marketing purposes. There’s no gray area for implied consent here. The HIPAA Privacy Rule treats this as a hard requirement, not a best practice, and OCR has pursued enforcement against organizations that assumed a patient’s silence meant approval.

A valid authorization isn’t just a checkbox. HHS guidance requires specific elements, and missing even one can invalidate the whole document:

• A clear description of the PHI to be used or disclosed
• The name of who is authorized to make the disclosure and who will receive it
• A stated purpose for the use, tied specifically to marketing
• An expiration date or event that ends the authorization
• The individual’s signature and date
• A statement of the right to revoke, and how to do it
• Notice that treatment cannot be conditioned on signing the authorization

That last point matters more than it looks. If a form implies a patient must opt in to receive care, the authorization is defective regardless of everything else being correct. Build your template around these seven elements first, then layer in branding and formatting.

When Communications Aren’t Marketing: HIPAA’s Exceptions

Not every PHI-based outreach needs a signed authorization. HIPAA carves out three exceptions that cover a lot of routine healthcare communication: face-to-face conversations between a provider and patient, promotional gifts of nominal value, and communications tied to treatment, payment, or health care operations.

A physician recommending a specific specialist during an office visit is exempt, even though it technically promotes a service. A refill reminder or a care coordination call falls under treatment, not marketing, as long as the content stays focused on the patient’s own care.

Where teams get into trouble is remuneration. If a pharmaceutical company or device maker pays you to send patients information about their product, that arrangement often converts an otherwise exempt communication into marketing, even when the content looks like a treatment reminder. Document the intent, the content, and any third-party payment behind every borderline communication, because that paper trail is what regulators and auditors will ask for first.

Pro Tip: Build a one-page decision log for every campaign that touches PHI. Note the purpose, whether money changed hands with a third party, and which exception (if any) you’re relying on. It takes five minutes and saves weeks during an audit.

Tracking Pixels, Analytics, and BAAs: Where Web Tech Creates PHI Risk

Your website’s tracking stack is probably leaking more PHI than your legal team realizes. HHS OCR has been explicit that tracking technologies like pixels and analytics scripts can create impermissible PHI disclosures the moment a visitor’s IP address gets paired with an appointment-booking page, a symptom search, or a specific provider lookup. That combination, even without a name attached, often counts as PHI under HIPAA.

The fix starts with a hard rule: any vendor that creates, receives, maintains, or transmits PHI on your behalf needs a signed BAA before their code touches your site. A cookie consent banner does not substitute for this. OCR has been direct that a banner alone is not a valid mechanism for disclosing PHI to ad-tech or analytics vendors, no matter how detailed the language is.

Run this audit sequence:

1. Inventory every tag, pixel, and analytics script currently firing on patient-facing pages.
2. Classify pages by clinical intent, treating appointment scheduling, symptom checkers, and condition-specific content as high-risk.
3. Gate high-intent pages behind authentication or strip identifying parameters before any third-party script loads.
4. Confirm a BAA exists for every vendor touching those pages, or remove the vendor.
5. Route de-identified aggregate data through a customer data platform instead of raw pixel fires where possible.

Pro Tip: Marketing and IT need to run this audit together. A marketer who doesn’t know what a pixel transmits, and an engineer who doesn’t know which pages are clinically sensitive, will each miss half the risk. Partner audits from firms like Affiliate Link Audit can help verify tracking architecture and consent flows before you launch.

TCPA and the One-to-One Consent Rule: What Changed for Outbound Marketing

The FCC’s one-to-one consent rule closed the lead-generator loophole that let a single opt-in checkbox authorize calls or texts from dozens of unrelated companies. Under the current standard, prior express written consent must be captured per seller, tied to a specific, clearly disclosed purpose. A blanket “I agree to be contacted by our partners” checkbox no longer satisfies TCPA requirements for healthcare outreach.

Revocation rules tightened alongside consent capture. When a patient or lead says stop, that revocation has to propagate everywhere: your CRM, your dialer, your SMS platform, and any downstream vendor. A revocation logged in one system but not another is exactly the kind of gap that turns into a class-action exposure.

Operational changes worth making immediately:

• Rebuild consent checkboxes so each seller or brand gets its own explicit, topic-linked disclosure.
• Store consent metadata (timestamp, source, exact language shown) directly in the CRM record, not just a boolean flag.
• Configure dialer campaigns to check current consent status before every call attempt, not just at lead intake.
• Set revocation to sync across every connected system within the same business day.

A platform like RevRing’s TCPA compliance guidance walks through how CRM and dialer settings need to change to match this consent architecture, particularly for teams running high call volumes.

FTC Rules on Health Claims, Reviews, and Testimonials

The FTC holds health and wellness advertising to a specific evidentiary bar: claims about efficacy, safety, or outcomes need competent and reliable scientific evidence behind them before they run. “Clinically proven” isn’t a marketing flourish under this standard; it’s a factual claim that needs a study to back it up.

Reviews and testimonials carry their own exposure. The FTC’s consumer reviews rule prohibits suppressing negative reviews, buying fake ones, or using testimonials that misrepresent typical patient results. Before-and-after imagery needs disclosure when results aren’t typical, and paid endorsements require clear disclosure of the payment relationship.

Recent enforcement shows this isn’t theoretical. The FTC’s 2025 action against telemedicine firm NextMed centered on misleading pricing claims and manipulated reviews, resulting in civil penalties and corrective disclosure requirements.

Keep these guardrails in place:

• Maintain a substantiation file for every claim that references efficacy, speed, or comparative results.
• Require disclosure language on any sponsored or incentivized review.
• Log every review removal request and the reason behind it.
• Review before-and-after content for representativeness, not just accuracy.

CMS Medicare Marketing Rules (MCMG): What’s Different for Medicare Audiences

Marketing to Medicare beneficiaries runs on a separate rulebook. CMS distinguishes marketing (content intended to draw a beneficiary toward a specific plan) from general communications (educational content with no steering intent), and the Medicare Communications and Marketing Guidelines apply strict rules the moment content crosses into marketing.

Timing restrictions matter here more than almost any other channel. Outreach during the Open Enrollment Period faces tighter limits on unsolicited contact, and CMS prohibits offering gifts or incentives that could be seen as inducements to enroll, even something as small as a gift card tied to a plan sign-up.

Key compliance points to segment for:

• Website and printed materials referencing specific plans need CMS-required disclosures on file.
• Comparisons between plans must avoid misleading or unsubstantiated superiority claims.
• Cold calls and door-to-door marketing to Medicare beneficiaries face outright prohibitions in most circumstances.
• Campaigns must be tagged by audience segment so Medicare-eligible leads get routed through CMS-specific preflight review before anything goes out.

Build a separate approval lane for any campaign touching Medicare-eligible audiences. Treating it as a variant of your general marketing workflow is how MCMG violations slip through.

A Practical Compliance Checklist for Healthcare Marketing Teams

Getting a campaign into a defensible state means running the same sequence every time, not improvising compliance review project by project.

1. Map every patient-facing page and tag its clinical intent level (low, medium, high).
2. Inventory every third-party script, pixel, and analytics tool currently active.
3. Classify each PHI touchpoint and confirm whether an exception applies or an authorization is needed.
4. Draft consent language that’s topic-specific, per-seller, and separate from general terms of service.
5. Confirm signed BAAs exist for every vendor touching PHI, using a checklist like RevRing’s BAA requirements guide as a starting template.
6. Set data retention limits and a documented breach-notification procedure.
7. Run quarterly test audits simulating what an OCR or FTC investigator would ask for.
8. Log every consent capture, revocation, and policy decision with timestamps.

An auditor won’t take your word that the program works. They’ll want evidence.

Operational Proof Points: Reducing Regulatory Risk With the Right Infrastructure

Most compliance failures in healthcare marketing don’t come from bad intent. They come from fragmented systems where consent lives in one tool, call logs live in another, and nobody can produce a unified audit trail when OCR or the FTC comes asking.

RevRing’s healthcare industry infrastructure was built around that exact gap. Consent capture, revocation status, and call activity connect to a single CRM record instead of scattering across disconnected platforms. That structure gives compliance officers what they actually need during a review:

• A single source of truth for consent and revocation status per contact
• Audit logs that timestamp every call and message attempt against current consent
• HIPAA BAA support built into the vendor relationship, not bolted on afterward
• Workflow automation that respects Medicare-specific timing rules for segmented campaigns

If you’re evaluating your own stack, pair these capabilities with a documented escalation path: who reviews flagged campaigns, who signs off on new vendor BAAs, and who owns the quarterly audit. Infrastructure solves half the problem. Governance solves the other half.

State-Specific Healthcare Marketing Regulations That Add to Federal Rules

Federal rules set the floor, not the ceiling. States layer their own restrictions on top of HIPAA, TCPA, and FTC requirements, and healthcare marketers who only check federal boxes routinely miss state-level exposure.

Many states have their own mini-TCPA statutes with stricter consent requirements or private rights of action that make lawsuits easier to file than under federal law alone. Some states extend genetic information privacy protections beyond what HIPAA covers, which matters for any campaign referencing genetic testing, wellness screening, or predictive health data. Insurance marketing in particular often triggers state insurance department rules on top of CMS requirements when the product involves Medicare Advantage or supplemental plans.

State attorney general offices have also become more active in health-data privacy enforcement, often moving faster than federal regulators on cases involving deceptive health advertising to state residents. A campaign that’s technically HIPAA-compliant can still violate a state’s own health information privacy statute if PHI-adjacent data gets shared with marketing vendors without state-specific consent language.

The practical move: maintain a state-by-state matrix for any market where you run PHI-adjacent or Medicare-related campaigns, tracking consent requirements, private right-of-action exposure, and any state health-privacy statute that goes beyond HIPAA’s floor. Legal review by market, not just by federal rule, is what actually protects multi-state healthcare marketing programs.

Direct-to-Consumer Pharmaceutical Advertising Restrictions

DTC pharmaceutical advertising operates under its own layer of restriction that healthcare marketing teams adjacent to pharma partnerships need to understand, even when they’re not the ones running the ads directly.

The FDA requires that any DTC ad mentioning a drug’s name and its intended use also disclose major risks and side effects, either through the “major statement” in broadcast ads or the brief summary in print. Broadcast ads face additional requirements around providing adequate provision for consumers to get full prescribing information, typically through a website reference or toll-free number.

Comparative claims between drugs face heightened scrutiny. A DTC ad implying superiority over a competing treatment needs substantiation that meets FTC’s competent and reliable scientific evidence standard on top of FDA’s own advertising rules, since both agencies can act on misleading pharmaceutical marketing.

Healthcare organizations that co-market with pharmaceutical partners, such as running patient education campaigns sponsored by a drug manufacturer, need to watch the remuneration issue raised earlier in HIPAA’s marketing exceptions. If a pharma company pays for the campaign and it references a patient’s health information to target them, that arrangement often needs a HIPAA authorization even if the content reads as educational. Keep the FDA disclosure requirements, the FTC substantiation standard, and the HIPAA authorization question as three separate checks on any DTC-adjacent campaign, not one combined review.

Social Media and Influencer Marketing Rules in Healthcare

Social platforms didn’t get a carve-out from any of these rules, and that’s where a lot of healthcare organizations get tripped up. A Facebook pixel on a landing page follows the same OCR tracking guidance as any other website tag. A sponsored post from a health influencer follows the same FTC endorsement disclosure rules as a print testimonial.

Influencer partnerships in healthcare carry a specific risk: influencers making health claims about a product or service need the same competent and reliable scientific evidence backing those claims that the brand itself would need. If an influencer says a supplement “cured” their condition, that claim exposes both the influencer and the sponsoring healthcare brand to FTC action, because the disclosure obligation doesn’t disappear just because a third party said the words.

Comment sections and DMs on social platforms create their own PHI exposure. A patient commenting about their specific condition on a healthcare provider’s post, and a staff member responding with anything referencing that patient’s care, can create a public HIPAA disclosure. Train social teams to move any specifics of care into a private, secure channel immediately rather than responding in the public thread.

Platform-native tracking pixels (Meta Pixel, TikTok Pixel, LinkedIn Insight Tag) deserve the same audit treatment as any other analytics script. If a pixel fires on a page where someone searches symptoms or books an appointment, the same BAA and gating requirements from the earlier tracking section apply regardless of which platform hosts the pixel.

Patient Testimonials and Endorsements: What Healthcare Marketing Law Restricts

Patient testimonials sit at the intersection of two separate rule sets, and clearing one doesn’t clear the other. HIPAA governs whether you can use a patient’s story or image at all, since a testimonial referencing someone’s specific condition or treatment is PHI, and using it in marketing generally requires a signed authorization separate from any general consent form. That authorization needs the same required elements covered earlier: a specific description, an expiration, and a clear revocation right.

Clearing HIPAA doesn’t clear the FTC. The FTC’s testimonial rules require that any results shown be typical, or that the ad disclose what results a typical patient can expect if the testimonial reflects an atypical outcome. A dramatic before-and-after result from one patient, presented without context, risks a deceptive advertising claim even with a valid HIPAA authorization on file.

Compensation adds a third layer. If a patient received payment, a discount, or free services in exchange for their testimonial, that relationship needs clear disclosure under FTC endorsement guidelines. Silence on the compensation question is itself the violation, not just outright deception about it.

Build a single intake process for any patient testimonial that captures three things at once: a HIPAA-compliant authorization specific to marketing use, a note on whether the results shown are typical or need a disclosure, and documentation of any compensation provided. Handling these separately, or skipping one because the other cleared, is how testimonial-based campaigns end up violating a rule nobody checked.

Patient Data Privacy Beyond HIPAA: GDPR and Other Considerations

HIPAA covers PHI held by covered entities and their business associates, but it doesn’t cover every piece of health-adjacent data your marketing team touches. Wellness app data, fitness tracker information, and health-related search behavior captured outside a covered entity’s systems often fall outside HIPAA’s scope entirely, even though it’s sensitive in exactly the way patients assume is protected.

For healthcare organizations serving international patients or operating digital properties accessible to European visitors, the GDPR adds obligations HIPAA doesn’t address: explicit consent requirements for processing health data, the right to request data deletion, and restrictions on transferring personal data outside the European Economic Area. A healthcare marketing site with no European operations can still trigger GDPR exposure if it knowingly markets to or tracks EU visitors.

The practical gap most teams miss: HIPAA governs the clinical relationship, but marketing technology often collects data adjacent to that relationship, things like browsing behavior, wellness quiz answers, or newsletter engagement, that isn’t PHI under HIPAA’s definition but is still sensitive personal data under state privacy laws or GDPR. Treat any health-adjacent data collected through marketing channels, not just clinical records, as requiring its own consent and retention policy. Running one privacy framework for “HIPAA data” and ignoring everything else is the gap regulators are increasingly testing.

Why Privacy-First Marketing Wins in Healthcare

Privacy-first isn’t a constraint on healthcare marketing performance. It’s what keeps a campaign running long enough to produce results, instead of getting pulled mid-flight by a BAA gap or a consent failure. The trade-off between personalization and minimum-necessary PHI use is real, but the smarter path is de-identified segmentation, not raw personal data. Build one governance owner with clear escalation authority, and treat every new vendor or channel as a fresh compliance review, not an exception to the last one.

— Marc

Where to Learn More About RevRing’s Healthcare Marketing Tools

Revring built its healthcare workflows around the exact gaps this article covers: fragmented consent records, missing BAAs, and audit trails that don’t hold up under review. Instead of layering another point solution onto tools you already have, Revring connects consent capture, dialer activity, and CRM records into one system your compliance team can actually audit on demand.

Start by reviewing the healthcare industry page to see how consent workflows and compliance infrastructure fit your current stack, then check pricing plans starting at $39.99 per month per seat for the Starter tier. When you request a demo, ask specifically about BAA support, per-seller consent capture, and how revocation syncs across your CRM and dialer. That’s the fastest way to see whether your next platform closes the gaps this article just walked through, or adds another one.

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.

Sources

• Hhs
• One-to-One Consent Rule for TCPA Prior Express Written Consent Frequently Asked Questions
• Health-Products Compliance Guidance | Federal Trade Commission
• Medicare communications and marketing guidelines (MCMG) | CMS

FAQ

What Are the 5 P’s of Healthcare Marketing?

The traditional 5 P’s are product, price, place, promotion, and people, adapted from general marketing theory to healthcare’s specific patient-centered context. In practice, healthcare marketers layer compliance considerations, like HIPAA authorization and FTC substantiation, onto each of these five elements before any campaign launches.

What Are the CMS Medicare Marketing Guidelines for 2026?

CMS’s Medicare Communications and Marketing Guidelines set rules on timing (including Open Enrollment Period restrictions), prohibited inducements like gifts tied to enrollment, and required disclosures on plan-specific materials. The full MCMG document distinguishes true marketing from general educational communications, which face fewer restrictions.

What Are the 7 P’s of Marketing in the Healthcare Industry?

The extended 7 P’s add process, physical evidence, and sometimes performance to the original 5, reflecting healthcare’s emphasis on care delivery consistency and the tangible patient experience. These frameworks are marketing theory tools, not regulatory requirements. HIPAA, FTC, FCC, and CMS rules apply regardless of which marketing model a team uses to plan campaigns.

What Are the Major Healthcare Regulations in the US?

The core federal framework includes HIPAA (enforced by HHS/OCR) for patient privacy and PHI use, the FTC Act for deceptive advertising and health claims, the TCPA (enforced by the FCC) for calls and texts, and CMS rules for Medicare-specific marketing. State laws add another layer, often with stricter consent or private right-of-action provisions than federal rules alone provide.

Does RevRing Help With HIPAA and TCPA Compliance?

Revring’s healthcare infrastructure includes HIPAA BAA support and consent capture workflows designed to track per-seller consent and revocation status in one CRM record. Current pricing and plan details are available on the RevRing pricing page.